Condition (MeSH)
Extensively Drug-Resistant Tuberculosis
ClinicalTrials.gov lists 23 trials for Extensively Drug-Resistant Tuberculosis or a narrower condition beneath it. National Institute of Allergy and Infectious Diseases (NIAID) has the most among industry and government lead sponsors, with 4.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
23 of the 23 trials are tagged with Extensively Drug-Resistant Tuberculosis itself; the rest are tagged with a narrower condition beneath it.
When did Extensively Drug-Resistant Tuberculosis trials start? (12)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Observational
Top of scale: 4
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2022 | 1 |
| 2021 | 1 |
| 2020 | 4 |
| 2019 | 2 |
| 2018 | 1 |
| 2017 | 2 |
| 2015 | 2 |
| 2012 | 1 |
| 2011 | 3 |
| 2010 | 3 |
Showing 10 of 12 earlier years.
No forecast is made for this condition: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Extensively Drug-Resistant Tuberculosis trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 1/2 | 1 |
| Phase 2 | 4 |
| Phase 2/3 | 4 |
| Phase 3 | 5 |
| Phase 4 | 1 |
| Observational | 6 |
How many Extensively Drug-Resistant Tuberculosis trials are recruiting? (4)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 1 |
| Completed | 20 |
| Terminated | 1 |
| Unknown status | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Extensively Drug-Resistant Tuberculosis trials? (5)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | 4 |
| Centers for Disease Control and Prevention | 1 |
| Centre for the AIDS Programme of Research in South Africa | 1 |
| Nearmedic Plus LLC | 1 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 |
Which drugs are being tested for Extensively Drug-Resistant Tuberculosis? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Bedaquiline | 9 |
| Clofazimine | 4 |
| Delamanid | 2 |
Interventions as named in the registry (12)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Zyvox - linezolid | 9 |
| Pretomid (Pa) | 7 |
| C: moxifloxacin | 5 |
| Pyrazinamide Oral Product | 3 |
| Levofloxacin 500 | 2 |
Showing 5 of 12 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Extensively Drug-Resistant Tuberculosis trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Electrocardiogram QT prolonged | 19 | 1 |
| Anaemia | 10 | 2 |
| Haemoptysis | 8 | 2 |
| Pneumonia | 7 | 2 |
| Psychotic disorder | 7 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Extensively Drug-Resistant Tuberculosis? (60)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
Showing 5 of 60 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.